文献速递银屑病与炎症性皮肤病

银屑病系统治疗与死亡风险降低:PSOLAR巢式病例对照分析

Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A nested case-control analysis.
PubMed 文献 · J Am Acad Dermatol · 2020-08-13

该研究基于PSOLAR登记数据库,采用巢式病例对照设计,评估系统治疗对银屑病患者死亡风险的影响。共纳入12,090例患者,341例死亡,按1:4匹配1364例对照。结果显示,近3个月内生物制剂暴露与死亡风险降低相关,无论治疗时长;甲氨蝶呤仅在暴露≥1年时显示保护作用。

要点

  • 生物制剂近3个月内暴露与死亡风险降低相关,OR为0.08-0.09。
  • 甲氨蝶呤仅暴露≥1年时与死亡风险降低相关,OR为0.08。
  • 观察性研究存在未测混杂,需谨慎解读因果关联。

核心结论

  • 生物制剂治疗与中重度银屑病患者死亡风险降低相关,无论治疗时长。
  • 甲氨蝶呤仅在暴露≥1年时与死亡风险降低相关。

研究设计与样本

  • 巢式病例对照分析,数据来自PSOLAR登记。
  • 共12,090例患者,341例死亡,按1:4匹配1364例对照。
  • 匹配因素包括年龄、种族、性别和地理区域。

主要发现

  • 近3个月内生物制剂暴露<1年者死亡风险OR为0.08(95%CI 0.03-0.23)。
  • 近3个月内生物制剂暴露≥1年者死亡风险OR为0.09(95%CI 0.06-0.13)。
  • 甲氨蝶呤暴露≥1年者死亡风险OR为0.08(95%CI 0.02-0.28)。

临床怎么用

  • 对于中重度银屑病患者,生物制剂治疗可能与降低死亡风险相关。
  • 甲氨蝶呤需持续暴露≥1年才可能观察到死亡风险降低。

局限性

  • 观察性研究设计,存在未测混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effects of systemic therapy on mortality risk among patients with psoriasis are not fully understood. OBJECTIVE: To evaluate the impact of systemic treatment on mortality risk in patients enrolled in the Psoriasis Longitudinal Assessment and Registry. METHODS: Nested case-control analyses were performed to estimate mortality risk. Cases were defined as patients who died while participating in the Psoriasis Longitudinal Assessment and Registry. Cases were matched (1:4) with controls by age, race, sex, and geographic region. Evaluated treatments included methotrexate, ustekinumab, and tumor necrosis factor α inhibitors. Exposure was defined as at least 1 dose of treatment within 3 months before death and was stratified by duration of therapy. RESULTS: Among 12,090 patients, 341 deaths occurred, matched to 1364 controls. Biologic treatment within the preceding 3 months was protective against mortality versus no exposure: odds ratio (OR) for exposure of less than 1 year, 0.08 (95% confidence interval [CI], 0.03-0.23); OR for exposure of 1 year or longer, 0.09 (95% CI, 0.06-0.13). Methotrexate was protective against mortality only with exposure for 1 year or longer (OR, 0.08; 95% CI, 0.02-0.28). LIMITATIONS: Observational studies are subject to unmeasured confounding. CONCLUSIONS: Biologic therapy was associated with reduced mortality risk in patients with moderate to severe psoriasis, regardless of treatment duration; methotrexate reduced risk only with exposure for 1 year or longer.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Langley RG, Poulin Y, Srivastava B, et al. Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A nested case-control analysis. J Am Acad Dermatol. 2020. PMID: 32798580. doi:10.1016/j.jaad.2020.08.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。